Menu
← Oncology Approval Tracker
FDA DECISION ·
Bizengri
zenocutuzumab-zbco · Partner Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced, unresectable or metastatic cholangiocarcinoma with an NRG1 fusion and progression on or after systemic therapy.
LAMPGEN ANALYSIS
Why it matters
This extends a targeted bispecific into a rare molecularly defined biliary cancer. FDA evaluated response in a small efficacy population within the eNRGy study.
What research teams should watch
Early molecular testing and access to assays that can identify NRG1 fusions can affect referral. State the study denominator when describing response.
PRIMARY RECORDS